Detection of circulating neoplastic cells by reverse-transcriptase polymerase chain reaction in malignant melanoma: association with clinical stage and prognosis. Amifostine pretreatment for ...

ORION CORPORATION PRESS RELEASE 8 JANUARY 2026 at 12.00 EET Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in ...

NovoTTF-100L System, combined with chemotherapy, is FDA-approved for malignant pleural mesothelioma, marking the first new treatment in over 15 years. The STELLAR trial showed a median overall ...

Microarray ANALYSIS of t(11;18)(Q21;Q21)-positive and -negative gastrointestinal MALT lymphomas. Background: Malignant peritoneal mesothelioma (MPM) is a rare disease and prognosis is poor. The ...

MTG Biotherapeutics (MTG), an immuno-oncology company developing novel therapeutics for the treatment of cancer, today announced that the US Food and Drug Administration has granted Orphan Drug ...

Patients with mesothelioma may be getting a new second-line treatment, thanks to results from a recent immunotherapy trial. For patients with malignant pleural mesothelioma — which makes up about 90 ...

Nivolumab monotherapy is an effective treatment option for relapsed malignant mesothelioma (MM), according to research presented today at the International Association for the Study of Lung Cancer ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated with ...

A novel treatment for advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to new research. Transarterial ...

Doctors at the Mesothelioma Treatment Center at Baylor College of Medicine and Baylor St. Luke’s Medical Center are now offering mesothelioma patients a new FDA-approved device as part of their ...